BearingPoint Elects Stefan Penthin to Be the Next Managing Partner of the Global Firm
27.3.2024 13:59:00 EET | Business Wire | Press release
With, as planned, the final term of its current Managing Partner coming to an end, the partnership of the independent management and technology consultancy, BearingPoint, has elected Stefan Penthin to be its next Managing Partner, effective September 1, 2024. He will succeed Kiumars Hamidian, who successfully headed the business since his appointment in 2018, and did not stand for re-election after two terms in office as planned. The new Managing Partner was elected by the BearingPoint Partners in a collaborative process based on the principle of One Partner - One Vote.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240327335930/en/
Stefan Penthin will be the next worldwide Managing Partner of BearingPoint. (Photo: Business Wire)
Stefan Penthin comments: “I am honored to be entrusted as the next Managing Partner of our firm and am fully committed to the long-term success of our clients and the partnership. We have extraordinary people and a strong portfolio driven by the spirit of innovation and entrepreneurship. We will go further with our mission, creating lasting outcomes for our clients, and enabling people to succeed.”
Stefan Penthin has been with BearingPoint for 23 years and became a Partner in 2012. He is a member of the firm’s global Management Committee and of the German Executive Committee. He is also the global leader for BearingPoint’s market segments as well as the global leader for Automotive & Industrial Manufacturing. Stefan brings more than 25 years of experience in business consulting to the table and has been leading large global consulting projects and business transformation programs with a focus on automotive and manufacturing industries. Stefan’s functional expertise is centered around supply chain management, operational excellence, as well as production and logistics optimization. His clients include major multinational corporations as well as specialized segment players across the globe.
Kiumars Hamidian comments: “Congratulations to Stefan Penthin! With him taking up the role as Managing Partner in September, I know that our business is in the safest possible hands. Stefan is a highly trusted leader and has been exceptionally successful in creating client value, he has excellent abilities, deep industry expertise, and an outstanding commitment to our values and principles. In his role as the global leader for our market segments, Stefan has made a significant contribution to the outstanding business success of our firm with revenues increasing to over EUR 1 billion. The transition process is well on schedule, and fully supported by the entire partnership of our firm.”
Kiumars Hamidian, Managing Partner at BearingPoint since 2018, guided BearingPoint successfully through the pandemic and to new heights. Under his leadership, revenues rose to more than EUR 1 billion and the number of employees increased to more than six thousand in 2023.
During Hamidian’s time in office, 13 acquisitions were delivered, a new subsidiary in India opened, and the US and Asia business expanded. In addition, the first joint venture (Arcwide) has been successfully established, and BearingPoint RegTech and BearingPoint Beyond (today flourishing as independent companies) have been successfully spun off. Moreover, BearingPoint established its purpose “Together, we are more than business,” and embraced a people-centric culture. Once the handover to Stefan Penthin is complete, Kiumars Hamidian will start his official early retirement phase in early 2025.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provide IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
X: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327335930/en/
Contact information
Press
Alexander Bock
Global Senior Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
